Influcein capsules 75mg, 10pcs

Composition

Auxiliary substances:

calcium hydrophosphate-25 mg,

pregelatinized corn starch-46.3 mg,

croscarmellose sodium-7.2 mg,

sodium stearyl fumarate-1.5 mg,

talc-1.5 mg.

Capsule body composition:

gelatin – 45.2956 mg, titanium dioxide-0.9244 mg;

Capsule cap composition:

gelatin – 29.1077 mg, titanium dioxide-0.3971 mg, quinoline yellow dye-0.2739 mg, sunny sunset yellow dye-0.0013 mg

Pharmacological action

Antiviral agent. It is a prodrug whose active metabolite (oseltamivir carboxylate) selectively inhibits neuraminidase of influenza virus types A and B.

Neuraminidase is a glycoprotein that catalyzes the cleavage of the bond between terminal sialic acid and sugar, thereby promoting the spread of the virus in the respiratory tract (exit of virions from the infected cell and penetration into the cells of the respiratory epithelium, preventing inactivation of the virus by epithelial mucus).

Oseltamivir carboxylate acts outside of cells and competitively inhibits viral neuraminidase.

Inhibits the growth of influenza virus in vitro and suppresses viral replication and pathogenicity in vivo.

Reduces the release of influenza A and B viruses from the body.

It does not affect the production of antibodies in response to the introduction of inactivated influenza vaccine.

The resistance rate of clinical virus isolates is 2%.

Indications

Influenza types A and B.

Recommendations for use

The method of use and dosage regimen of a particular drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and dosage regimen.

Taken orally, regardless of food intake.

During treatment, the intake should be started no later than 2 days after the development of symptoms of the disease at a dose of 75 mg 2 times/day for 5 days. An increase in the dose of more than 150 mg / day does not lead to an increase in the effect.

For the prevention of influenza types A and B in adults-75 mg 1-2 times / day for 6 weeks. (during a flu epidemic). The maximum daily dose for adults is 150 mg.

In patients with creatinine clearance less than 30 ml / min, the dose is reduced to 75 mg 1 time / day for 5 days.

Contraindications

Chronic renal failure (creatinine clearance less than 10 ml / min), hepatic insufficiency, hypersensitivity to oseltamivir.

Side effects

From the digestive system:  nausea, vomiting (usually when taken in high doses, or in the first days of treatment); rarely-diarrhea, abdominal pain.

From the central nervous system:  insomnia, dizziness, headache.

Respiratory system disorders: nasal congestion, sore throat, cough.

Other services:  feeling tired, weak.

Interaction

Drugs that block tubular secretion increase the concentration of the active metabolite by 2-3 times (due to inhibition of the process of active tubular secretion in the kidneys), which does not require dose adjustment.

Description

Capsules are solid, gelatinous, No. 1; the lid is yellow, the body is white; the contents of the capsules are a mixture of granules and powder of almost white color or a compressed mass of almost white color that crumbles when lightly pressed.

Functional features

After oral use, it is almost completely absorbed from the gastrointestinal tract, absorption does not depend on food intake. It has a “first pass” effect through the liver. Under the action of intestinal and hepatic esterases, it is converted into an active metabolite. 75% of the oral dose enters the systemic circulation in the form of an active metabolite, less than 5% – in the form of a starting substance. Plasma concentrations of both the prodrug and active metabolite are dose-proportional.

Medium V_d active metabolite – 23 l. Binding to plasma proteins is 3%.

It is excreted as an active metabolite mainly by the kidneys through glomerular filtration and tubular secretion. T_1/2 of oseltamivir – 1-3 hours. Oseltamivir carboxylate is not further metabolized and is excreted by the kidneys, its T_1/2 – 6-10 hours. Renal clearance is 18.8 l/h. It is excreted through the intestines-less than 20%.

In elderly patients (65-78 years), the concentration of the active metabolite at steady state is 25-35% higher than in younger patients. In patients with renal insufficiency, the rate of elimination of oseltamivir carboxylate is inversely proportional to the value of creatinine clearance.

Special instructions

Use with caution in children.

In patients with hepatic insufficiency, the safety and efficacy of oseltamivir have not been established.

There are no data on the safety of using oseltamivir with creatinine clearance less than 10 ml/min.

Active ingredient

Oseltamivir

Conditions of release from pharmacies

By prescription

Dosage form

Capsules

Indications

Flu, Flu Prevention